Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
or

Acelyrin Inc (SLRN)

Acelyrin Inc (SLRN)
2.55 x 1 2.57 x 1
Post-market by (Cboe BZX)
2.60 +0.43 (+19.82%) 02/21/25 [NASDAQ]
2.55 x 1 2.57 x 1
Post-market 2.57 -0.03 (-1.17%) 17:41 ET
Quote Overview for Fri, Feb 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
2.37
Day High
2.64
Open 2.56
Previous Close 2.17 2.17
Volume 12,567,522 12,567,522
Avg Vol 3,224,431 3,224,431
Stochastic %K 79.93% 79.93%
Weighted Alpha -48.28 -48.28
5-Day Change +0.54 (+26.21%) +0.54 (+26.21%)
52-Week Range 1.85 - 8.89 1.85 - 8.89
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 217,707
  • Shares Outstanding, K 100,326
  • Annual Sales, $ 0 K
  • Annual Income, $ -381,640 K
  • EBIT $ -336 M
  • EBITDA $ -346 M
  • 60-Month Beta 1.85
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.41

Options Overview Details

View History
  • Implied Volatility 158.41% ( +3.89%)
  • Historical Volatility 72.20%
  • IV Percentile 70%
  • IV Rank 18.39%
  • IV High 741.10% on 02/12/25
  • IV Low 27.11% on 10/22/24
  • Put/Call Vol Ratio 0.01
  • Today's Volume 1,102
  • Volume Avg (30-Day) 109
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 1,842
  • Open Int (30-Day) 1,277

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.84
  • Number of Estimates 4
  • High Estimate -0.68
  • Low Estimate -1.03
  • Prior Year -0.75
  • Growth Rate Est. (year over year) -12.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.85 +40.92%
on 02/11/25
Period Open: 1.99
2.64 -1.52%
on 02/21/25
+0.61 (+30.65%)
since 01/21/25
3-Month
1.85 +40.92%
on 02/11/25
Period Open: 4.33
5.03 -48.26%
on 11/25/24
-1.73 (-39.95%)
since 11/21/24
52-Week
1.85 +40.92%
on 02/11/25
Period Open: 7.64
8.89 -70.74%
on 03/01/24
-5.04 (-65.97%)
since 02/21/24

Most Recent Stories

More News
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences

SLRN : 2.60 (+19.82%)
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

SLRN : 2.60 (+19.82%)
ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease

SLRN : 2.60 (+19.82%)
ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab

SLRN : 2.60 (+19.82%)
ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis

SLRN : 2.60 (+19.82%)
ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights

SLRN : 2.60 (+19.82%)
ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024

SLRN : 2.60 (+19.82%)
ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease

SLRN : 2.60 (+19.82%)
Acelyrin (SLRN) Q3 2023 Earnings Call Transcript

SLRN earnings call for the period ending September 30, 2023.

SLRN : 2.60 (+19.82%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Acelyrin, Inc. - SLRN

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Acelyrin, Inc. ("Acelyrin" or the "Company") (NASDAQ: SLRN). Such investors are...

SLRN : 2.60 (+19.82%)

Business Summary

Acelyrin Inc. is a clinical biopharma company. It focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep. Acelyrin Inc. is based in Agoura Hills, California.

See More

Key Turning Points

3rd Resistance Point 2.98
2nd Resistance Point 2.81
1st Resistance Point 2.70
Last Price 2.60
1st Support Level 2.43
2nd Support Level 2.26
3rd Support Level 2.15

See More

52-Week High 8.89
Fibonacci 61.8% 6.20
Fibonacci 50% 5.37
Fibonacci 38.2% 4.53
Last Price 2.60
52-Week Low 1.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements